Beyond Air, INC 10-Q quarterly reports

Beyond Air, Inc. filed its Q2 2026 10-Q, detailing continued operational losses and a focus on securing future funding, alongside progress in its medical device and biopharmaceutical segments.

Beyond Air, Inc. reported significantly reduced net losses and increased revenue for the six months ended September 30, 2025, driven by LungFit PH commercialization and recent capital raises.

Beyond Air, Inc. reported a significant reduction in net loss and increased revenue for the quarter ended June 30, 2025, driven by LungFit PH commercialization and international expansion, despite ongoing liquidity concerns.

Beyond Air's Q3 2025 results show increased revenue but continued net losses as the company focuses on commercialization and strategic adjustments.

Beyond Air's Q2 2025 results show increased revenue but continued losses, alongside securing new financing and restructuring debt.

Beyond Air's Q1 2025 results show increased revenue from LungFit PH sales, but the company continues to operate at a loss while investing in research and development.

Beyond Air, Inc. reported its financial results for the third quarter of fiscal year 2024, highlighting revenue growth and strategic advancements in its nitric oxide technology platform.